Controversially, the presence of a high density of FoxP3+ Treg in CRC has also been associated with improved survival in stage II and stage III CRC patients [66,83] and in relapsed CRC patients undergoing chemotherapy or chemoimmunotherapy [90]. The gene discussed is FOXP3; the disease is colorectal carcinoma.